Evidence map›Paper›PMID 36455200›Full record

ArticleBlood2023

DDX41-associated susceptibility to myeloid neoplasms.

Hideki Makishima, Teresa V Bowman, Lucy A Godley

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Germline DDX41 Variants: Current Understanding and Future Directions.Current hematologic malignancy reports · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Role of DEAD/DEAH-box helicases in immunity, infection and cancers.Cell communication and signaling : CCS · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Hideki MakishimaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.ORCID 0000-0001-5983-8578
Teresa V BowmanDepartment of Developmental and Molecular Biology, Gottesman Institute for Stem Cell Biology and Regenerative Medicine, Department of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.
Lucy A GodleyDepartments of Medicine and Human Genetics, Section of Hematology/Oncology, The University of Chicago, Chicago, IL.ORCID 0000-0003-1914-9158
Albert Einstein College of Medicine · USKyoto University · JPUniversity of Chicago · US

Funding

Crosstalk of Splicing and Signaling in HSPC fate choicesR01DK121738 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI BOWMAN, TERESA V · 2020 to 2023
$1.6M
Identification of novel regulators of HSC specification and maturationR01DK131445 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI BOWMAN, TERESA V · 2021 to 2023
$868k
NIDDK NIH HHS R01 DK121738NIDDK NIH HHS R01 DK131445
6 · The paper itself

Abstract

Deleterious germ line DDX41 variants confer risk for myeloid neoplasms (MNs) and less frequently for lymphoid malignancies, with autosomal dominant inheritance and an estimated prevalence of 3% among MNs. Germ line DDX41 variants include truncating alleles that comprise about two-thirds of all alleles, missense variants located preferentially within the DEAD-box domain, and deletion variants. The identification of a truncating allele on tumor-based molecular profiling should prompt germ line genetic testing because >95% of such alleles are germ line. Somatic mutation of the wild-type DDX41 allele occurs in about half of MNs with germ line DDX41 alleles, typically in exons encoding the helicase domain and most frequently as R525H. Several aspects of deleterious germ line DDX41 alleles are noteworthy: (1) certain variants are common in particular populations, (2) MNs develop at older ages typical of de novo disease, challenging the paradigm that inherited cancer risk always causes disease in young people, (3) despite equal frequencies of these variants in men and women, men progress to MNs more frequently, suggesting a gender-specific effect on myeloid leukemogenesis, and (4) individuals with deleterious germ line DDX41 variants develop acute severe graft-versus-host disease after allogeneic hematopoietic cell transplantation with wild-type donors more than others unless they receive posttransplant cyclophosphamide, suggesting a proinflammatory milieu that stimulates donor-derived T cells. Biochemical studies and animal models have identified DDX41's ability to interact with double-stranded DNA and RNA:DNA hybrids with roles in messenger RNA splicing, ribosomal RNAs or small nucleolar RNAs processing, and modulation of innate immunity, disruption of which could promote inflammation and drive tumorigenesis.

Indexed as

DEAD-box RNA HelicasesLeukemia, MyeloidMyeloproliferative DisordersAnimalsFemaleGerm-Line MutationHumansMaleRNA, MessengerDDX41 protein, humanDEAD-box RNA HelicasesRNA, Messenger

Identifiers

PMID36455200
PMCPMC10356560
OpenAlexW4310506366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.